Plain-English translation of NCT07248176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called allogeneic CAR-T cells targeting BCMA for adults with multiple myeloma that has come back or is no longer responding to standard therapy. These are immune cells that have been specially engineered in a lab to recognize and fight cancer cells. The study will measure how safe this treatment is and how well it works.
Multiple myeloma is a blood cancer that often returns or becomes resistant to standard treatments. This trial exists because doctors need better options for patients whose cancer no longer responds to conventional therapy, and this medication represents a new approach using the body's own immune system to attack the disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an infusion of the engineered immune cells. The study will closely monitor your safety and response to the treatment through blood tests, scans, and clinical visits. This is a small early-stage trial with only 6 participants, so you would receive personalized medical attention while the research team gathers important data about how this new treatment works.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Sponsor
Bioray Laboratories
Collaborators
Shanghai Tongji Hospital, Tongji University School of Medicine
Enrollment target
~6 participants
Started
April 2025
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ping Li, phD
13564181131
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.